Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) reactivation in an MS patient with resolved HBV infection receiving ocrelizumab. HBV reactivation was monitored with HBV-DNA and HBV surface antigen periodic assessment. Anti-HBV treatment with entecavir was started after HBV-DNA detection. Ocrelizumab can reactivate viral replication in patients with resolved HBV infection. HBV reactivation monitoring seems an effective and safe option for the management of these patients. More studies are needed to assess the optimal management of HBV reactivation in MS patients on ocrelizumab treatment.

Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis / Ciardi, Maria R; Iannetta, Marco; Zingaropoli, Maria A; Salpini, Romina; Aragri, Marianna; Annecca, Rosanna; Pontecorvo, Simona; Altieri, Marta; Russo, Gianluca; Svicher, Valentina; Mastroianni, Claudio M; Vullo, Vincenzo. - In: OPEN FORUM INFECTIOUS DISEASES. - ISSN 2328-8957. - 6:1(2019), pp. 1-3. [10.1093/ofid/ofy356]

Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis

Ciardi, Maria R;Iannetta, Marco;Zingaropoli, Maria A;Annecca, Rosanna;Pontecorvo, Simona;Russo, Gianluca;Mastroianni, Claudio M;Vullo, Vincenzo
2019

Abstract

Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) reactivation in an MS patient with resolved HBV infection receiving ocrelizumab. HBV reactivation was monitored with HBV-DNA and HBV surface antigen periodic assessment. Anti-HBV treatment with entecavir was started after HBV-DNA detection. Ocrelizumab can reactivate viral replication in patients with resolved HBV infection. HBV reactivation monitoring seems an effective and safe option for the management of these patients. More studies are needed to assess the optimal management of HBV reactivation in MS patients on ocrelizumab treatment.
2019
cd20; hbv; biologics; entecavir; liver; prophylaxis
01 Pubblicazione su rivista::01i Case report
Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis / Ciardi, Maria R; Iannetta, Marco; Zingaropoli, Maria A; Salpini, Romina; Aragri, Marianna; Annecca, Rosanna; Pontecorvo, Simona; Altieri, Marta; Russo, Gianluca; Svicher, Valentina; Mastroianni, Claudio M; Vullo, Vincenzo. - In: OPEN FORUM INFECTIOUS DISEASES. - ISSN 2328-8957. - 6:1(2019), pp. 1-3. [10.1093/ofid/ofy356]
File allegati a questo prodotto
File Dimensione Formato  
Ciardi_Reactivation_2019.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 184.19 kB
Formato Adobe PDF
184.19 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1239131
Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 46
  • ???jsp.display-item.citation.isi??? 39
social impact